GIA
CRSP icon

GHP Investment Advisors’s CRISPR Therapeutics CRSP Stock Holding History

GHP Investment Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100
Closed -$5.4K – 999
2024
Q2 		$5.4K Hold
100
– – ﹤0.01% 773
2024
Q1 		$6.82K Hold
100
– – ﹤0.01% 684
2023
Q4 		$6.26K Hold
100
– – ﹤0.01% 694
2023
Q3 		$4.43K Hold
100
– – ﹤0.01% 798
2023
Q2 		$4.96K Hold
100
– – ﹤0.01% 771
2023
Q1 		$4.52K Hold
100
– – ﹤0.01% 783
2022
Q4 		$4.07K Hold
100
– – ﹤0.01% 792
2022
Q3 		$7K Hold
100
– – ﹤0.01% 737
2022
Q2 		$6K Hold
100
– – ﹤0.01% 775
2022
Q1 		$6K Buy
+100
New +$6.28K ﹤0.01% 797

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

GHP Investment Advisors's CRSP Position: Q3 2024 in Review

GHP Investment Advisors sold out of CRISPR Therapeutics (CRSP) in Q3 2024, closing a stake of 100 shares — an estimated $5.4K sold.

GHP Investment Advisors first reported a position in CRSP in Q1 2022 and held it in 10 quarters. The position peaked at $7K in Q3 2022. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

  • GHP Investment Advisors reported no remaining CRISPR Therapeutics position as of Q3 2024 after selling out during the quarter.
  • GHP Investment Advisors sold 100 CRISPR Therapeutics shares in Q3 2024, an estimated $5.4K.
  • GHP Investment Advisors first reported a position in CRISPR Therapeutics in Q1 2022 and held it in 10 quarters.
  • GHP Investment Advisors's CRISPR Therapeutics position peaked at $7K in Q3 2022.
  • 416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on GHP Investment Advisors's 13F filing for Q3 2024, filed 24 Oct 2024.